Development, licensing and marketing agreement for regenerative medicine therapyDevelopment, Licensing and Marketing Agreement • August 11th, 2020
Contract Type FiledAugust 11th, 2020
DealdocDevelopment, Licensing and Marketing Agreement • July 8th, 2024
Contract Type FiledJuly 8th, 2024Development, licensing and marketing agreement for early stem cell therapy for patients following myocardial infarction
Amendment date: Jan 09 2015Development, Licensing and Marketing Agreement • November 21st, 2021 • New York
Contract Type FiledNovember 21st, 2021 JurisdictionAdamas Pharmaceuticals has received a $25 million milestone payment from Forest Laboratories related to the development of MDX-8704.